

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7438

Applicants	N.A. Williams and T.R. Hirst
US Nat. Phase Entry	PCT/GB99/02970
	Filing Date: 7 March 2001
Title of Application	Peptide Fragments of Cholera Toxin B or Enterotoxin B as Vaccine Adjuvants

Box Sequence
 Commissioner of Patents
 and Trademarks
 Washington, DC 20231

SUBMISSION OF COMPUTER
READABLE COPY OF SEQUENCE LISTING

Dear Sir:

Submitted herewith is a computer readable copy on a 3.5" 1.44 Mb diskette of the Sequence Listings for the sequences in the above-identified application, with each listing assigned a separate identifier as set forth in the application. Each submitted sequence listed herein and each computer readable copy on the enclosed diskette are the same, and are the same as what was originally filed internationally on 7 September 1999. The section was reformatted to conform to U.S. practice, but no new matter is presented.

Respectfully submitted,

March 7, 2001

Mary M. Krinsky
 Mary M. Krinsky, Reg. No. 32423
 79 Trumbull Street
 New Haven, CT 06511-3708
 (203) 773-9544

I hereby certify that this correspondence is today being deposited with the U.S. Postal Service as Express Mail, No. EL572277083US, to the Commissioner of Patents and Trademarks, Washington, DC 20231.

7 March 2001

Mary M. Krinsky
 Mary M. Krinsky

SEQUENCE LISTING

<110> Williams, Neil Andrew
<120> Hirst, Timothy Raymond
<130> Peptide Fragments of Cholera Toxin B or Enterotoxin B as Vaccine Adjuvants
<140> 7438
<141> 2001-03-07
<150> PCT/GB99/02970
<151> 1999-09-07
<160> 6
<170> MS DOS

<210> 1
<211> 27
<212> DNA
<213> artificial sequence
<220>
<223> encodes heptapeptide of SEQ ID NO 2
<400> 1

gaagtaccag gtagtcaaca tatacat 27

<210> 2
<211> 7
<212> PRT
<213> *E. coli*
<220>
<222> 51...57
<223> isolated or synthetic EtxB β 4- α 2 loop fragment
derivable from human variant *E. coli*
<400> 2

Glu Val Pro Gly Ser Gln His
5

<210> 3
<211> 12
<212> PRT
<213> *E. coli*
<220>
<222> 50...61
<223> isolated or synthetic EtxB β 4- α 2 loop fragment
derivable from human variant *E. coli*
<400> 3

Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln
5 10

<210> 4
<211> 21
<212> PRT
<213> *E. coli*
<220>
<222> 45...65
<223> isolated or synthetic EtxB β 4- α 2 loop fragment
derivable from human variant *E. coli*
<400> 4

Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp
5 10 15

Ser Gln Lys Lys Ala Ile
20

<210> 5
<211> 21
<212> PRT
<213> *E. coli*
<220>
<222> 45...65
<223> isolated or synthetic EtxB β 4- α 2 loop fragment
derivable from porcine *E. coli*
<400> 5

Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp
5 10 15

Ser Gln Lys Lys Ala Ile
20

<210> 6
<211> 13
<212> PRT
<213> artificial sequence
<220>
<223> control peptide used in Example 5
<400> 6

Leu Arg Asn Glu Thr Thr Thr Lys Gly Asp Tyr Cys
5 10

04/786648

JCOZ Rec'd PCT/PTO 07 MAR 2001
PCT/GB99/02970

WO 00/14114

1

SEQUENCE LISTING

SEQ ID No 1

5

GAA GTA CCA GGT AGT CAA CAT ATA GAT

SEQ ID No 2

10 EVPGSQH

SEQ ID No 3

15 VEVPGSQHIDSQ

SEQ ID No 4

GATFQVEVPGSQHIDSQKKAI

20 **SEQ ID No 5**

GETFQVEVPGSQHIDSQKKAI

25